कृपया अन्य खोज का प्रयास करें
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Erika F. Augustine | - | 2017 | Member of Scientific Advisory Board |
Donald A. Wuchterl | 54 | 2021 | Independent Director |
Steven Gray | - | 2017 | Member of Scientific Advisory Board |
Michael Amoroso | 46 | 2020 | Chairman of the Board |
Vishwas Seshadri | 48 | 2021 | President, CEO & Director |
Faith L. Charles | - | 2021 | Independent Director |
Mark J. Alvino | 56 | 2021 | Independent Director |
Jonathon Mink | - | 2017 | Member of Scientific Advisory Board |
John Cooper | - | 2017 | Member of Scientific Advisory Board |
Leila Alland | 61 | 2021 | Independent Director |
Christine Berni-Silverstein | 40 | 2016 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है